It is now looking very unlikely that patients with liver cancer will get access to Bayer’s Stivarga on the NHS, after cost regulators issued final draft guidelines rejecting funding for the drug in this setting.
Original Article: Liver cancer patients barred from NHS access to Bayer’s Stivarga
NEXT ARTICLE